Trichomoniasis Market

 Market Overview:

The trichomoniasis market reached a value of USD 48.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 78.2 Billion by ​2035​, exhibiting a growth rate (CAGR) of 4.49% during ​2025-2035​.

The trichomoniasis market has been comprehensively analyzed in IMARC's new report titled "Trichomoniasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Trichomoniasis, or trich, is a prevalent sexually transmitted disease (STD). Trichomoniasis is caused by a microscopic one-celled parasite known as Trichomonas vaginalis. It affects women more than men, older women more than younger women, and African American women more than white or Hispanic women. Women with trichomoniasis frequently experience vaginal discharge, uncomfortable intercourse, urinary tract infection symptoms, vaginal itching, or pelvic pain. Men may be asymptomatic, or they might have symptoms such as penile discharge, testicular pain, dysuria, urinary frequency, or cloudy urine. Symptoms often appear between 5 and 28 days following exposure. Diagnosing trichomoniasis commonly involves a comprehensive clinical assessment and physical investigation. The healthcare provider may also conduct a microscopic examination, in which a sample of vaginal or penile discharge is examined under a microscope to look for the parasite, Trichomonas vaginalis. In a few cases, numerous other studies, such as rapid-antigen dipstick tests and nucleic acid amplification tests (NAATs), might be performed to detect the genetic material of the parasite.

The escalating cases of sexually transmitted infection in which the parasitic protozoan is transmitted through sexual contact, including vaginal, oral, or anal sex, are primarily driving the trichomoniasis market. In addition to this, the inflating utilization of antiparasitic medications, such as metronidazole, tinidazole, and secnidazole, to reduce itching, discharge, and discomfort within days, is also creating a positive outlook for the market. Moreover, the widespread adoption of vaginal metronidazole gel, since it works by directly targeting Trichomonas vaginalis in the vaginal environment, thereby lowering vaginal irritation and restoring normal flora in patients, is further bolstering the market growth. Apart from this, the rising usage of pH-balancing agents on account of their several benefits, like reduced risk of reinfection, encouraged the growth of beneficial bacteria, and maintained vaginal health, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of polymerase chain reaction testing, which is a highly sensitive and specific method for diagnosing the ailment using vaginal swabs or urine samples is expected to drive the trichomoniasis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the trichomoniasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trichomoniasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trichomoniasis market in any manner.

Recent Developments:

• In July 2024, Evofem broadened its commercial offering with the acquisition of SOLOSEC (secnidazole) 2g oral granules, an FDA-approved oral antibiotic for the treatment of trichomoniasis in people 12 years of age and older.

Drugs:

Secnidazole is a nitroimidazole antibiotic used to treat trichomoniasis. The antimicrobial and antiprotozoal activity of secnidazole is accounted for by the nitro group in the imidazole ring. When secnidazole enters the target pathogen, bacterial or parasite nitroreductase enzymes decrease the nitro group, resulting in radical anions and reactive intermediates. Radical anions and reactive intermediates deplete thiols, break DNA helixes, disrupt bacterial or parasite protein synthesis and replication, and eventually kill vulnerable isolates of Gram-positive bacteria, Gram-negative bacteria, and T. vaginalis.

Metronidazole is a nitroimidazole used to treat confirmed trichomoniasis caused by Trichomonas vaginalis. The drug generates reactive nitroso radicals, which bind to DNA, causing strand breakage, impaired replication, and protein dysfunction. The resulting cellular damage and metabolic disruption lead to parasite death. This bactericidal and antiprotozoal action effectively eliminates the infection.

Tinidazole is both a prodrug and an antiprotozoal agent. Trichomonas reduces the nitro group of tinidazole via a ferredoxin-mediated electron transport mechanism. The reduction generates a free nitro radical, which is thought to be responsible for the antiprotozoal activity. It is thought that the harmful free radicals covalently bond to the DNA, causing DNA damage and cell death.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the trichomoniasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the trichomoniasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current trichomoniasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the trichomoniasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the trichomoniasis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the trichomoniasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of trichomoniasis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of trichomoniasis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of trichomoniasis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with trichomoniasis across the seven major markets?
• What is the size of the trichomoniasis patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of trichomoniasis?
• What will be the growth rate of patients across the seven major markets?

Trichomoniasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for trichomoniasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the trichomoniasis market?
• What are the key regulatory events related to the trichomoniasis market?
• What is the structure of clinical trial landscape by status related to the trichomoniasis market?
• What is the structure of clinical trial landscape by phase related to the trichomoniasis market?
• What is the structure of clinical trial landscape by route of administration related to the trichomoniasis market?